PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Celecoxib	13-22	ATP binding cassette subfamily C member 4	Homo sapiens	49-53	
26141932-7	2016	DAMI cells treated with celecoxib, diclofenac, and naproxen showed a significant increase in MRP4-mRNA expression compared to the mock culture.	Celecoxib	24-33	ATP binding cassette subfamily C member 4	Homo sapiens	93-97	
17878487-0	2007	Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications.	Celecoxib	0-9	ATP binding cassette subfamily C member 4	Homo sapiens	18-23	
17005917-10	2007	Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration.	Celecoxib	35-44	ATP binding cassette subfamily C member 4	Homo sapiens	45-49	
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Celecoxib	67-76	ATP binding cassette subfamily C member 4	Homo sapiens	17-21	
16454695-10	2006	Preincubation of MRP4/HepG2 cells with BSO (200 microM) for 24 hr, celecoxib (50 microM), or MK-571 (100 microM) for 2 hr significantly increased the accumulation of TPT over 10 min in MRP4/HepG2 cells by 28.0%, 37.3% and 32.5% (P < 0.05), respectively.	Celecoxib	67-76	ATP binding cassette subfamily C member 4	Homo sapiens	185-189	
18690847-3	2008	The aim of the study was to investigate the induction by celecoxib of some multidrug resistance proteins, MRP1, MRP2, MRP4 and MRP5, involved in the transport of irinotecan and 5-FU.	Celecoxib	57-66	ATP binding cassette subfamily C member 4	Homo sapiens	118-122	
18690847-8	2008	In both cell lines celecoxib induced MRP4 and MRP5 over-expression at RNA and protein levels.	Celecoxib	19-28	ATP binding cassette subfamily C member 4	Homo sapiens	37-41	
18690847-10	2008	Cryoimmunoelectron microscopy showed increased MRP4 and MRP5 immunolabeling in celecoxib treated cells both at cytoplasmic level and along the plasma membrane.	Celecoxib	79-88	ATP binding cassette subfamily C member 4	Homo sapiens	47-51	
16454695-8	2006	BSO, MK-571, celecoxib, or diclofenac sensitised MRP4/HepG2 cells to TPT cytotoxicity and partially reversed MRP4-mediated resistance to TPT.	Celecoxib	13-22	ATP binding cassette subfamily C member 4	Homo sapiens	109-113	
16132345-11	2005	The resistance of MRP4 to various CPTs tested was significantly reversed in the presence of dl-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamylcysteine synthetase inhibitor), MK571, celecoxib, or diclofenac (all MRP4 inhibitors).	Celecoxib	185-194	ATP binding cassette subfamily C member 4	Homo sapiens	18-22	
16132345-12	2005	In addition, the accumulation of CPT-11 and SN-38 over 120 min in MRP4/HepG2 cells was significantly reduced compared to V/HepG2 cells, whereas the addition of celecoxib, MK571, or BSO significantly increased their accumulation in MRP4/HepG2 cells.	Celecoxib	160-169	ATP binding cassette subfamily C member 4	Homo sapiens	231-235